Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

The company’s pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

The company was incorporated in 2018 and is based in Grasonville, Maryland.

OS Therapies Incorporated

Country	United States
Founded	2018
IPO Date	Aug 1, 2024
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Paul Romness

Contact Details

Address: 115 Pullman Crossing Road, Suite 103 Grasonville, Maryland 21638 United States
Phone	410 297 7793
Website	ostherapies.com

Stock Details

Ticker Symbol	OSTX
Exchange	NYSEAMERICAN
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$4.00
CIK Code	1795091
CUSIP Number	68764Y207
ISIN Number	US68764Y2072
Employer ID	82-5118368
SIC Code	2834

Key Executives

Name	Position
Paul A. Romness M.P.H.	Founder, Chairman, President and Chief Executive Officer
Christopher P. Acevedo	Chief Financial Officer
Dr. Robert G. Petit II, Ph.D.	Chief Medical Officer and Chief Scientific Officer
Jack Doll	Chief of Staff
Gerald E. Commissiong	Chief Business Officer

Latest SEC Filings

Date	Type	Title
May 18, 2026	10-Q	Quarterly Report
May 15, 2026	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Apr 30, 2026	8-K	Current Report
Apr 2, 2026	8-K	Current Report
Apr 2, 2026	424B5	Filing
Mar 31, 2026	8-K	Current Report
Mar 31, 2026	424B7	Filing
Mar 31, 2026	10-K	Annual Report
Mar 6, 2026	D	Notice of Exempt Offering of Securities
Mar 6, 2026	8-K	Current Report

View All SEC Filings